The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.
This conversation is about a 21-year old male's success with using finasteride, minoxidil and ketoconazole shampoo to regrow his hair. He increased the finasteride dosage from 1mg 3x per week to 1 mg daily for maximum results. People in the thread commended him on his progress.
A 23-year-old noticed crown thinning and started using 1.25mg finasteride, biotin supplements, biotin/collagen shampoo, and 1% nizoral shampoo. After 3 months, they reported improvement and side effects that subsided after 2 months.
The user reduced serum DHT by 60% using Advanced Trichology's natural DHT blocker but saw no improvement in hair loss. They are considering switching to finasteride due to its proven effectiveness in inhibiting scalp DHT.
PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.
Keratin fusion bonds are discussed as an alternative to clip-on hair patches for men with diffused thinning. The conversation explores different styling options for hair loss.
A user diagnosed with AGA is seeking advice on hair loss treatments, comparing topical Minoxidil, Spironolactone, and Finasteride to oral medications and natural methods like dermastamping, PRP, and LED light. They are concerned about side effects and effectiveness, especially given their existing fatigue.